A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

Trial Profile

A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Jul 2019 to 16 Feb 2021.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Apr 2017 Planned number of patients changed from 162 to 650.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top